BALB/cJ and BALB/cJ nu/un mice injected with live tumor cells CT26 |
100–200 μg |
Intratumoral on Days 5, 10 and 15 |
Retarded progression of injected tumors |
[81] |
BNX nu/un male mice mice injected with PC-3 cells |
5 mg/kg/day |
Gavage 3 days per week for 4 weeks |
Reduced tumor growth |
[53] |
Athymic nude mice injected with PC-3 cells |
5 mg/kg body weight |
Subcutaneous injection every two days for 14 days |
Suppressed PC-3 tumor growth and induced apoptosis |
[51] |
Female athymic nude mice injected subcutaneously with AsPC-1 tumor cells |
2.5 mg/kg body weight |
Five times a week |
Suppressed growth of tumor xenografts without adverse effects |
[61] |
5 mg/kg body weight |
Three times a week |
[61] |
Male athymic nu/nu mice injected with U266 cells |
1 mg/kg |
Twice a week for 3 weeks |
Inhibited growth of U266 xenograft tumors |
[60] |
Male Athymic nude mice injected subcutaneously with T24 cells |
5 mg/kg |
Subcutaneous injection every 3 days for 4 weeks |
Slowed growth of xenograph tumors |
[67] |
Female triple deficient beige/nude/xid mice (BNX) injected with MDA-MB231 cells |
5 mg/kg |
Oral gavage 3 days per week for 4 weeks |
Decrease the size of tumors by 50% |
[46] |
Male nude mice injected subcutaneously with H69 cells |
10 mg/kg body weight |
Solid diet until tumors of the control group reached 2000 mm3
|
Tumor growth suppression |
[68] |
Female BALB/c athymic nude mice injected subcutaneously with Colo 205 cells |
1 mg/kg |
Intraperitoneal injected. Four weeks of treatment |
Inhibition of tumor growth |
[46] |
3 mg/kg |
Female athymic nude mice injected subcutaneously with AsPC-1 tumor cells |
2.5 mg/kg |
Orally fed 5 days a week for 6 weeks |
Reduced tumor SOD activity by 60% and increased the ratio of oxidized glutathione to glutathione |
[62] |
Male BALB/c (nu/nu) athymic nude mice injected subcutaneously with PANC-1 cells |
5 mg/kg body weight |
Gavage 3 days per week for 4 weeks |
Inhibited the growth of pancreatic cancer PANC-1 cell xenografts. |
[41] |